This technology is a method for treating germinal center (GC) diffuse large B-cell lymphoma (DLBCL) and other lymphomas using an epigenetic combination therapy targeting EZH2 dysregulation and HDAC-mediated epigenetic repression.
Germinal center (GC) diffuse large B-cell lymphoma (DLBCL) is strongly linked to mutations in epigenetic modulators, such as histone methyltransferases (e.g. EZH2, MLL) and histone acetyltransferases (e.g. EP300, CREBBP). EZH2 activating mutations and loss of histone acetyltransferase function can switch off genes that normally keep abnormal cell growth in check, allowing lymphoma cells to survive and grow more aggressively. Approximately 30% of DLBCL patients relapse following first-line treatment, requiring second-line chemotherapy followed by autologous stem cell transplantation (AutoSCT). However, some patients are not eligible for AutoSCT or relapse afterward, highlighting the need for alternative targeted therapies. Furthermore, there are currently no treatments for GC-DLBCL utilizing a drug combination targeting EZH2 and HDACs.
This technology describes the use of a combination of drugs to target epigenetic modulators as a therapy for GC-DLBCL. This combination therapy elicits a synergistic effect by dual inhibition of EZH2 and HDAC. By inhibiting EZH2-mediated repression and HDAC-mediated chromatin tightening, this approach may restore gene expression for regulating lymphoma cell growth, differentiation, and survival. A BCL2 inhibitor may also be combined to further promote cancer cell death by blocking anti-apoptotic survival signaling. As a result, this treatment has the potential to offer improved outcomes for GC-DLBCL patients compared with other chemotherapeutic approaches, including higher overall response rates, longer response durations, and improved progression-free survival.
This technology has been validated in a panel of lymphoma cell lines and in a xenograft mouse model of GC-DLBCL.
Patent Issued (US 11,597,933)
IR CU17258
Licensing Contact: Jerry Kokoshka